Advagene Biopharma Co., Ltd. (TPEX:6709)
Taiwan
· Delayed Price · Currency is TWD 26.50
0.00 (0.00%)
Apr 29, 2026, 12:13 PM CST
Advagene Biopharma Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 55.33 | 52.82 | 65.19 | 18.01 | 14.33 | Upgrade
|
| Short-Term Investments | 79.5 | 149.5 | 60 | 85 | 209.5 | Upgrade
|
| Cash & Short-Term Investments | 134.83 | 202.32 | 125.19 | 103.01 | 223.83 | Upgrade
|
| Cash Growth | -33.36% | 61.61% | 21.54% | -53.98% | -18.16% | Upgrade
|
| Other Receivables | 23.39 | 21.96 | 20.27 | 19.2 | 16.59 | Upgrade
|
| Receivables | 23.39 | 21.96 | 20.27 | 19.2 | 16.59 | Upgrade
|
| Prepaid Expenses | 0.79 | 0.54 | 0.95 | 3.61 | 3.57 | Upgrade
|
| Total Current Assets | 159.01 | 224.82 | 146.41 | 125.82 | 244 | Upgrade
|
| Property, Plant & Equipment | 7 | 6.89 | 1.04 | 3.22 | 5.41 | Upgrade
|
| Other Intangible Assets | - | - | - | 9.81 | 9.02 | Upgrade
|
| Other Long-Term Assets | 0.5 | 0.5 | 0.48 | 1.98 | 1.98 | Upgrade
|
| Total Assets | 166.51 | 232.21 | 147.93 | 140.84 | 260.41 | Upgrade
|
| Accounts Payable | 1.46 | 0.75 | 0.87 | 0.56 | 0.56 | Upgrade
|
| Accrued Expenses | 8.06 | 4.7 | 5.99 | 6.05 | 5.79 | Upgrade
|
| Current Portion of Leases | 1.32 | 1.26 | - | 1.35 | 1.27 | Upgrade
|
| Other Current Liabilities | 0.78 | 0.4 | 1.11 | 0.46 | 0.65 | Upgrade
|
| Total Current Liabilities | 11.61 | 7.11 | 7.97 | 8.42 | 8.27 | Upgrade
|
| Long-Term Leases | 2.65 | 4.56 | - | 0.65 | 2.57 | Upgrade
|
| Total Liabilities | 14.26 | 11.67 | 7.97 | 9.08 | 10.84 | Upgrade
|
| Common Stock | 593.8 | 593.8 | 533.8 | 493.49 | 492.92 | Upgrade
|
| Additional Paid-In Capital | - | 90 | 60.39 | 3.12 | 95.12 | Upgrade
|
| Retained Earnings | -441.55 | -463.26 | -454.22 | -364.85 | -338.47 | Upgrade
|
| Shareholders' Equity | 152.25 | 220.54 | 139.96 | 131.76 | 249.57 | Upgrade
|
| Total Liabilities & Equity | 166.51 | 232.21 | 147.93 | 140.84 | 260.41 | Upgrade
|
| Total Debt | 3.97 | 5.82 | - | 2.01 | 3.84 | Upgrade
|
| Net Cash (Debt) | 130.87 | 196.5 | 125.19 | 101 | 220 | Upgrade
|
| Net Cash Growth | -33.40% | 56.96% | 23.95% | -54.09% | -17.87% | Upgrade
|
| Net Cash Per Share | 2.20 | 3.60 | 2.48 | 2.05 | 4.51 | Upgrade
|
| Filing Date Shares Outstanding | 59.38 | 59.38 | 53.38 | 49.35 | 49.29 | Upgrade
|
| Total Common Shares Outstanding | 59.38 | 59.38 | 53.38 | 49.35 | 49.29 | Upgrade
|
| Working Capital | 147.4 | 217.72 | 138.44 | 117.39 | 235.72 | Upgrade
|
| Book Value Per Share | 2.56 | 3.71 | 2.62 | 2.67 | 5.06 | Upgrade
|
| Tangible Book Value | 152.25 | 220.54 | 139.96 | 121.95 | 240.55 | Upgrade
|
| Tangible Book Value Per Share | 2.56 | 3.71 | 2.62 | 2.47 | 4.88 | Upgrade
|
| Machinery | 2.99 | 1.21 | 1.36 | 1.4 | 3.09 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.